AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22336590 — intervention group
Group type: EXPERIMENTAL
Intervention: diet with exercise
Number of subjects: 60
Study 22336590 — intervention group
Group type: EXPERIMENTAL
Intervention: diet with sibutramine
Number of subjects: 60
Study 22336590 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline fat mass plus change in weight and HOMA(IR) at week 4
Number of subjects: 60
Study 20130094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DHA (400 mg/d)
Number of subjects: 33
Study 20130094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA (1200 mg/d)
Number of subjects: 33
Study 20130094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17670879 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine with 1:100,000 epinephrine
Number of subjects: 60
Study 17670879 — intervention group
Group type: COMPARATOR
Intervention: 2 percent lidocaine with 1:100,000 epinephrine
Number of subjects: 60
Study 15167512 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 149
Study 15167512 — intervention group
Group type: COMPARATOR
Intervention: Partial thyroidectomy
Number of subjects: 149
Study 15167512 — intervention group
Group type: EXPERIMENTAL
Intervention: I scan post-surgery
Number of subjects: 149
Study 15167512 — intervention group
Group type: EXPERIMENTAL
Intervention: I treatment
Number of subjects: 149
Study 12225613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (5 ml/kg per day for 3 consecutive days)
Number of subjects: 42
Study 12225613 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard sepsis therapy without immunoglobulin)
Number of subjects: 42
Study 12225613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin
Number of subjects: 42
Study 12225613 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 9620108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 2
Study 9620108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 7522200 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐RT group (n = 94)
Number of subjects: 184
Study 7522200 — intervention group
Group type: COMPARATOR
Intervention: RT group (n = 90)
Number of subjects: 184
Study 2537433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron grafts
Number of subjects: 12
Study 2537433 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE grafts
Number of subjects: 12
Study 5338377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 injections of 1 ml of aluminium-phosphate-adsorbed tetanus toxoid more than 6 weeks apart
Number of subjects: 1618
Study 5338377 — intervention group
Group type: COMPARATOR
Intervention: 2 or 3 injections of influenza-virus vaccine
Number of subjects: 1618
Study 31813770 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 31813770 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 0
Study 31813770 — intervention group
Group type: EXPERIMENTAL
Intervention: Central obesity (CO)
Number of subjects: 0
Study 31813770 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity metrics (BMI, WC, CO)
Number of subjects: 0
Study 28958022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 1091
Study 28958022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) for overweight participants (BMI < 30 kg/m2)
Number of subjects: 1091
Study 28958022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) for obese participants (BMI ≥ 30 kg/m2)
Number of subjects: 1091
Study 28958022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) overall
Number of subjects: 1091
Study 28958022 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Diabetes Support and Education - DSE)
Number of subjects: 1091
Study 28257886 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment for Performance (P4P)
Number of subjects: 200
Study 26677086 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized hydrogymnastics exercise program (12 weeks, 5 times a week, 50 minutes per session, heart rate reserve 40-50% for weeks 1-6, 50-60% for weeks 7-12)
Number of subjects: 26
Study 26677086 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise)
Number of subjects: 26
Study 23470301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 22
Study 23470301 — intervention group
Group type: COMPARATOR
Intervention: Higher-Volume Moderate-Intensity Endurance Exercise (END)
Number of subjects: 22
Study 21600165 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple regimen (PPI + bismuth + amoxicillin + furazolidone, 10 days) plus dental plaque removal treatment
Number of subjects: 104
Study 21600165 — intervention group
Group type: COMPARATOR
Intervention: Quadruple regimen (PPI + bismuth + amoxicillin + furazolidone)
Number of subjects: 104
Study 18082960 — intervention group
Group type: EXPERIMENTAL
Intervention: Microskin (sprayed on skin camouflage) for 5 weeks
Number of subjects: 20
Study 18082960 — intervention group
Group type: COMPARATOR
Intervention: Microskin (sprayed on skin camouflage) for 5 weeks (wait-list group after initial 7 weeks)
Number of subjects: 20
Study 18082960 — intervention group
Group type: EXPERIMENTAL
Intervention: Microskin (sprayed on skin camouflage)
Number of subjects: 20
Study 15951393 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809
Study 15951393 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 809
Study 15951393 — intervention group
Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 809
Study 15951393 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 809
Study 12835542 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated textiles
Number of subjects: 15
Study 12835542 — intervention group
Group type: COMPARATOR
Intervention: Cotton
Number of subjects: 15
Study 10506598 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m(2) every 3 weeks
Number of subjects: 40
Study 10506598 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 250 mg/m(2) with amifostine 910 mg/m(2)
Number of subjects: 40
Study 8895273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine with fentanyl 3 micrograms/mL (60 micrograms)
Number of subjects: 56
Study 8895273 — intervention group
Group type: COMPARATOR
Intervention: Chloroprocaine
Number of subjects: 56
Study 1803834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (Glaxo's formulation)
Number of subjects: 12
Study 1803834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (Veteran's formulation)
Number of subjects: 12
Study 1803834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (both formulations)
Number of subjects: 12
Study 6133153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin-ticarcillin
Number of subjects: 254
Study 6133153 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin-ticarcillin
Number of subjects: 254
Study 6133153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 254
Study 6133153 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 254
Study 30626424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ATP combined with fluoxetine (20 mg/day)
Number of subjects: 42
Study 30626424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of PCr combined with fluoxetine (20 mg/day)
Number of subjects: 42
Study 30626424 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) combined with fluoxetine (20 mg/day)
Number of subjects: 42
Study 30227457 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min arm-cranking exercise at 50% V̇O2max (A-trial)
Number of subjects: 14
Study 30227457 — intervention group
Group type: COMPARATOR
Intervention: 30-min leg-cycling exercise at 50% V̇O2max (C-trial)
Number of subjects: 14
Study 26796660 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray coagulation
Number of subjects: 151
Study 26796660 — intervention group
Group type: COMPARATOR
Intervention: Forced coagulation
Number of subjects: 151
Study 25195134 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) plus Prednisone (P) regimens (standard therapy)
Number of subjects: 7677
Study 25195134 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) combinations (D + other drug combinations)
Number of subjects: 7677
Study 25195134 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials and arms as a single unit
Number of subjects: 7677
Study 21987581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone phosphate, 1%, as adjunctive therapy
Number of subjects: 500
Study 21987581 — intervention group
Group type: COMPARATOR
Intervention: Placebo as adjunctive therapy
Number of subjects: 500
Study 19188272 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation with maintained unsupported spontaneous breathing (APRV), n = 13
Number of subjects: 37
Study 19188272 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation with pressure support (SIMV), n = 10
Number of subjects: 37
Study 19188272 — intervention group
Group type: COMPARATOR
Intervention: Comparison between APRV and SIMV
Number of subjects: 37
Study 17197130 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate RT (minimum radiation dose delivered: 4300 cGy for neoadjuvant RT or 4700 cGy for adjuvant RT; completion of RT in <44 days for neoadjuvant RT or <49 days for adjuvant RT)
Number of subjects: 788
Study 17197130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate RT
Number of subjects: 788
Study 17197130 — intervention group
Group type: EXPERIMENTAL
Intervention: No RT
Number of subjects: 788
Study 15964867 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus event-recorder
Number of subjects: 0
Study 15964867 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12477219 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGhaler dry powder inhaler with salbutamol (200 microg) at high peak inhaled flow rate (60 l/min)
Number of subjects: 10
Study 12477219 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGhaler dry powder inhaler with salbutamol (200 microg) at low peak inhaled flow rate (30 l/min)
Number of subjects: 10
Study 10516187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for 1, 3, and 5 seconds
Number of subjects: 10
Study 10516187 — intervention group
Group type: COMPARATOR
Intervention: Cycling for 5 seconds at loads of 0, 25, 50, and 75 W
Number of subjects: 10
Study 10516187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachycardia preceding hypotension
Number of subjects: 10
Study 7881698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (rhDNase), administered daily for 24 weeks
Number of subjects: 0
Study 7881698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (rhDNase)
Number of subjects: 0
Study 2039814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of nifedipine and atenolol
Number of subjects: 15
Study 2039814 — intervention group
Group type: COMPARATOR
Intervention: Atenolol alone
Number of subjects: 15
Study 2039814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard and urinary recovery of nifedipine metabolite
Number of subjects: 15
Study 7048247 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine, dosage: 1175 to 1500 mg/day, duration: 4 to 5 months
Number of subjects: 46
Study 7048247 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 31939849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg methadone for spinal surgery
Number of subjects: 0
Study 31939849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methadone for cardiac surgery
Number of subjects: 0
Study 31939849 — intervention group
Group type: COMPARATOR
Intervention: 2 mg hydromorphone for spinal surgery
Number of subjects: 0
Study 31939849 — intervention group
Group type: COMPARATOR
Intervention: 12 μg/kg fentanyl for cardiac surgery
Number of subjects: 0
Study 29254858 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group using the Fracture Risk Assessment Tool (FRAX)
Number of subjects: 6233
Study 29254858 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual management)
Number of subjects: 6233
Study 29254858 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 6233
Study 26584456 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Nigella sativa Seed Oil (600 mg applied to the site of pain bis in die for 2 months)
Number of subjects: 52
Study 26584456 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Diclofenac (20 mg bis in die)
Number of subjects: 52
Study 26584456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24755148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 24755148 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 22445438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg, days 12-16)
Number of subjects: 40
Study 22445438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg, days 8-14)
Number of subjects: 40
Study 22445438 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily, days 8-14)
Number of subjects: 40
Study 20064899 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 63
Study 20064899 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonnic
Number of subjects: 63
Study 20064899 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 63
Study 18077065 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks low-intensity wheelchair training (3 times a week, 70 min, at 30% of heart rate reserve)
Number of subjects: 21
Study 18077065 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks low-intensity wheelchair training
Number of subjects: 21
Study 18077065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 21
Study 18077065 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (7 weeks training)
Number of subjects: 21
Study 15677604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 28
Study 15677604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12763985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate (80 mg/day of elemental iron daily; n=75)
Number of subjects: 144
Study 12763985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=69)
Number of subjects: 144
Study 10781776 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing for 6 weeks
Number of subjects: 84
Study 10781776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distant healing)
Number of subjects: 84
Study 10781776 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing
Number of subjects: 84
Study 10781776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 8807068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 5
Study 8807068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 5
Study 8807068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ciprofloxacin and clarithromycin)
Number of subjects: 5
Study 8807068 — intervention group
Group type: COMPARATOR
Intervention: Control (ciprofloxacin alone)
Number of subjects: 5
Study 1357070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg oral, every 6 hours for 48 hours) + Pyridostigmine (120 mg oral) + GHRH (100 micrograms i.v.)
Number of subjects: 8
Study 1357070 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (2 mg oral, every 6 hours for 48 hours) + Placebo + GHRH (100 micrograms i.v.)
Number of subjects: 8
Study 1357070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, every 6 hours for 48 hours) + Placebo + GHRH (100 micrograms i.v.)
Number of subjects: 8
Study 3899675 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 5 mg once daily
Number of subjects: 10
Study 3899675 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 25 mg once daily
Number of subjects: 10
Study 3899675 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 50 mg once daily
Number of subjects: 10
Study 3899675 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (various doses)
Number of subjects: 10
Study 2953270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram X kg‐1 X hr‐1
Number of subjects: 30
Study 2953270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microgram X kg‐1 X hr‐1
Number of subjects: 30
Study 2953270 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 28296349 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 0
Study 28296349 — intervention group
Group type: COMPARATOR
Intervention: Biguanides (BG)
Number of subjects: 0
Study 28296349 — intervention group
Group type: COMPARATOR
Intervention: α-glucosidase inhibitors (αGI)
Number of subjects: 0
Study 28296349 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas (SU)
Number of subjects: 0
Study 27385157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 48
Study 27385157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 40 mg twice a day
Number of subjects: 27
Study 24164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir 80 mg once a day
Number of subjects: 27
Study 24164420 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 27
Study 22741260 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at 2 Hz (Group II)
Number of subjects: 56
Study 22741260 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at 2 Hz/100 Hz (Group III)
Number of subjects: 56
Study 22741260 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 56
Study 20522788 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 146
Study 20522788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert inulin-based)
Number of subjects: 146
Study 18458306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 5 days
Number of subjects: 399
Study 18458306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 7 days
Number of subjects: 399
Study 18458306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 9 days
Number of subjects: 399
Study 18458306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 11 days
Number of subjects: 399
Study 18458306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 14 days
Number of subjects: 399
Study 18458306 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg twice a day for 7 days
Number of subjects: 399
Study 15670541 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion calcium (CLC)
Number of subjects: 3292
Study 12603644 — intervention group
Group type: EXPERIMENTAL
Intervention: Schultz-type autogenic training
Number of subjects: 25
Study 11253883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral pilocarpine (0.13 mg/ml in BSS)
Number of subjects: 30
Study 11253883 — intervention group
Group type: COMPARATOR
Intervention: BSS (control group)
Number of subjects: 30
Study 11253883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral pilocarpine
Number of subjects: 30
Study 9456075 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled intervention programs aimed at enhancing organizational structures and individual coping strategies
Number of subjects: 0
Study 9456075 — intervention group
Group type: COMPARATOR
Intervention: Regular video display technology
Number of subjects: 0
Study 1544615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 72
Study 1544615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3885685 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal neurolysis
Number of subjects: 0
Study 3885685 — intervention group
Group type: COMPARATOR
Intervention: Cutting of the carpal ligament (flexor retinaculum) alone
Number of subjects: 0
Study 31168046 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for STEMI
Number of subjects: 2
Study 31168046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)-guided PCI for AP
Number of subjects: 2
Study 31168046 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI for asymptomatic patients
Number of subjects: 2
Study 31168046 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy for STEMI
Number of subjects: 2
Study 31168046 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy for AP
Number of subjects: 2
Study 29338727 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Hp genotypes
Number of subjects: 5687
Study 29338727 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Hp levels
Number of subjects: 5687
Study 29338727 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Hp genotypes and Hp levels
Number of subjects: 5687
Study 26786091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 300
Study 26786091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24714360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG) vaccination at birth
Number of subjects: 390
Study 24714360 — intervention group
Group type: COMPARATOR
Intervention: Low cytokine responses to LPS and PHA
Number of subjects: 390
Study 24714360 — intervention group
Group type: COMPARATOR
Intervention: High cytokine responses to LPS and PHA
Number of subjects: 390